What 10 Analyst Ratings Have To Say About Allogene Therapeutics
Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter: Bullish Somewhat Bullish Indifferent…
JMP Securities Maintains Market Perform on Allogene Therapeutics, Lowers Price Target to $19
JMP Securities analyst Benjamin Chaiken maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market Perform and lowers the price target from $23 to $19.
Goldman Sachs Maintains Buy on Allogene Therapeutics, Lowers Price Target to $31
Goldman Sachs analyst Salveen Richter maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target from $35 to $31.
EF Hutton Reiterates Buy on Allogene Therapeutics, Maintains $15 Price Target
EF Hutton analyst Tony Butler reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $15 price target.
Allogene Therapeutics Q4 EPS $(0.66) Beats $(0.70) Estimate, Sales $47.00K Miss $60.00K Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.70) by 5.71 percent. This is a 22.22 percent decrease over losses of $(0.54) per share
Why Allogene Therapeutics Shares Are Seeing Blue Skies Today
Allogene Therapeutics Inc (NASDAQ: ALLO) shares are trading higher by 13.1% to $7.76 Tuesday morning after the company announced data from its Phase 1 UNIVERSAL trial of ALLO-715 has been published in Nature Medicine.
What Else?
Allogene Therapeutics Announces Publication In Nature Medicine Of Data From Its Phase 1 UNIVERSAL Study Of ALLO-715 For The Treatment Of Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that data from its Phase 1
JP Morgan Upgrades Allogene Therapeutics to Overweight, Lowers Price Target to $11
JP Morgan analyst Brian Cheng upgrades Allogene Therapeutics (NASDAQ:ALLO) from Neutral to Overweight and lowers the price target from $20 to $11.
Benzinga’s Top Ratings Upgrades, Downgrades For January 6, 2023
Upgrades Piper Sandler upgraded the previous rating for Aligos Therapeutics Inc (NASDAQ:ALGS) from Neutral to Overweight. Aligos Therapeutics…
Expert Ratings for Allogene Therapeutics
Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…